Francis deSouza, Illumina CEO (Photo by Kevin Dietsch/Getty Images)
November 16, 2022 10:53 AM ESTUpdated 11:21 AM
People

Il­lu­mi­na be­comes the lat­est domi­no in lay­offs trend, cut­ting around 5% of its work­force

Tyler Patchen

News Reporter

The third quar­ter blues are hit­ting bio­phar­ma hard as the past weeks have seen both big phar­mas and small­er biotechs ax­ing por­tions of their staff …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times